

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/020,634	12/14/2001	Ronenn Roubenoff	21629-004	1772	
	7590 01/31/2005		EXAM	EXAMINER	
MINTZ, LEVIN, COHN, FERRIS,			KWON, BRIAN YONG S		
GLOVSKY ar	id POPEO, P.C.				
One Financial	Center		ART UNIT	PAPER NUMBER	
Boston MA	02111		1614	1614	

DATE MAILED: 01/31/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

and the second s	Application No.	Applicant(s)	•
Advisory Action	10/020,634	ROUBENOFF ET AL.	
Advisory Action	Examiner	Art Unit	_
	Brian S Kwon	1614	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence address	_
THE REPLY FILED 02 November 2004 FAILS TO PLAC Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment which	ation. A proper reply to a n places the application in	
PERIOD FOR RE	PLY [check either a) or b)]		
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the condition of the con	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CFI of extension and the corresponding amount in the shortened statutory period for reply the later than three months after the mail	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension unt of the fee. The appropriate extensior originally set in the final Office action; or	ı n
<ul><li>1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF)</li></ul>	Brief must be filed within the pe		
2. The proposed amendment(s) will not be entered be	ecause:		
(a) X they raise new issues that would require further	er consideration and/or search (s	see NOTE below);	
(b) they raise the issue of new matter (see Note b	elow);		
(c) they are not deemed to place the application in issues for appeal; and/or	better form for appeal by mater	rially reducing or simplifying the	
(d)  they present additional claims without canceling	ng a corresponding number of fi	nally rejected claims.	
NOTE: See Continuation Sheet.		•	
$3.\square$ Applicant's reply has overcome the following rejection	ion(s):		
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed amendment	
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: See		dered but does NOT place the	
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly	
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims wo			
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>1-13</u> .			
Claim(s) withdrawn from consideration:	•		
8.☐ The drawing correction filed on is a)☐ appr	oved or b)  disapproved by th	ne Examiner.	
9. Note the attached Information Disclosure Statemen	t(s)( PTO-1449) Paper No(s)	•	
10. Other:		Zohol For	
		in the control of the	

Continuation of 2. NOTE: Applicant's narrowing of the ratio of the reduced folate and cobalamin to 125:1 would require further consideration and/or search.

Continuation of 5. does NOT place the application in condition for allowance because: optimization of known active and inactive ingredient in a composition is considered within the skill of the artisan, and the artisan would be motivated to determine optimum therapeutic amounts of said ingredients to maximize the therapeutic effects of the drug.

Cohn for